North Carolina startup Pairwise is applying gene-editing tools to blackberries in an effort to remove seeds and thorns while increasing output per acre. The approach seeks to cut water use and chemical inputs at the same time. Traditional breeding has long required decades and repeated trade-offs to achieve even one of those changes. Pairwise aims to deliver several improvements together in a shorter timeframe.
Precision Tools Meet Traditional Breeding Limits
Conventional crop improvement relies on crossing plants and selecting offspring over many generations. Corn alone carries roughly 40,000 genes, creating vast numbers of possible combinations and frequent unintended losses in flavor or yield. Gene editing allows researchers to adjust one trait at a time without mixing entire genomes. Pairwise scientists have used this method to edit high-performing blackberry varieties directly for seedlessness rather than crossing separate lines and hoping the results hold up.
The same platform supports work on peaches without pits and fruit or nut trees that reach first harvest in one or two years instead of three to eight. Partnerships with Bayer and Corteva extend the approach to row crops, including corn lines with more kernel rows and added resistance to heat, drought, and wind damage. These stacked edits represent the core practical advantage: multiple targeted changes without the long wait for conventional crosses to stabilize.
Early Products and Limited Commercial Reach
Pairwise introduced the first CRISPR-edited food product in the United States in 2023, a mustard green bred for milder taste. The company discontinued that item the following year to focus on other crops. Its only current offering is a high-yielding blackberry variety sold in limited quantities in Colombia. More than fifty regulatory approvals exist for five edited crops across nine countries, yet none have reached broad U.S. retail shelves.
Company executives project seedless, thornless blackberries could appear in American stores around 2030. The timeline reflects the remaining steps of field testing, scaling propagation, and distribution. In the meantime, the firm has shifted toward licensing its editing platform to larger partners rather than building consumer brands itself.
Regulatory Climate and Investment Realities
Most governments have treated gene-edited crops as accelerated versions of conventional breeding, avoiding the stricter rules applied to transgenic GMOs. The European Union recently moved to regulate many edited varieties similarly to standard crops. Livestock applications face tighter scrutiny, with U.S. regulators classifying edited animals under drug rules in some cases.
Funding for gene-editing startups has remained modest compared with other ag-tech sectors. Roughly three billion dollars has flowed into the space over the past decade. Broader venture interest in food and farming technologies declined sharply after 2021, partly because earlier high-profile companies struggled to reach sustained profitability. Pairwise has raised more than 160 million dollars and maintains collaborations with Mars, Sun World, and research institutions including the Gates Foundation.
Stakeholders and Practical Stakes
Farmers stand to gain from higher yields on existing land and reduced input costs. Smallholder growers in regions such as sub-Saharan Africa could benefit from resilient staples like edited cowpea or cassava that withstand drought and pests. Nonprofits working with Pairwise see potential labor savings for crops such as semi-dwarf yams traditionally tended by women.
Consumers may notice direct improvements in taste and convenience, such as seedless berries or easier-to-harvest fruit. Environmental outcomes depend on whether higher productivity actually reduces pressure to clear new farmland. Industry analysts note that past GMO controversies could still influence public reaction, even though edited crops have so far encountered fewer organized objections.
Path Forward Remains Measured
Gene editing offers speed and precision that conventional methods lack, yet commercial scale still requires years of testing and market development. Partners such as Bayer expect edited traits to appear in most new varieties within the next decade. Corteva has identified disease resistance in corn as a top priority, targeting a four-gene product by 2030.
The technology’s ultimate reach will depend on continued regulatory consistency, sustained investment, and grower adoption. If those conditions hold, edited crops could contribute to higher output with lower environmental footprints. Realization of that outcome, however, will unfold gradually rather than through sudden breakthroughs.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.